Lack of MG53 in human heart precludes utility as a biomarker of myocardial injury or endogenous cardioprotective factor
Frances A Lemckert, Adam Bournazos, Daniel M Eckert, Manuel Kenzler, Joanne M Hawkes, Tanya L Butler, Bradley Ceely, Kathryn N North, David S Winlaw, Jonathan R Egan, Sandra T Cooper
CARDIOVASCULAR RESEARCH | OXFORD UNIV PRESS | Published : 2016
AIMS: Mitsugumin-53 (MG53/TRIM72) is an E3-ubiquitin ligase that rapidly accumulates at sites of membrane injury and plays an important role in membrane repair of skeletal and cardiac muscle. MG53 has been implicated in cardiac ischaemia-reperfusion injury, and serum MG53 provides a biomarker of skeletal muscle injury in the mdx mouse model of Duchenne muscular dystrophy. We evaluated the clinical utility of MG53 as a biomarker of myocardial injury. METHODS AND RESULTS: We performed Langendorff ischaemia-reperfusion injury on wild-type and dysferlin-null murine hearts, using dysferlin deficiency to effectively model more severe outcomes from cardiac ischaemia-reperfusion injury. MG53 release..View full abstract
Awarded by Australian National Health and Medical Research Council
This work was supported by funding from the Australian National Health and Medical Research Council (Project Grants APP570744 to S.C. and K.N., APP1048814 to S.C., K.N., and J.E.; Career Development Fellowship APP1048816 to S.C.; Biomedical Postgraduate Award 633193 to F.L.) and the Jain Foundation (to S.C.).